Conatus Pharmaceuticals Shares Dive After Failed Clinical Trial
Shares of Conatus Pharmaceuticals (Nasdaq:CNAT) have taken a dive, dropping over 30%, after releasing the results from their Phase 2b clinical trial.
The POLT-HCV-SVR clinical trial, which studied emiscaran in liver transplant patients …
Sonoma Pharmaceuticals FDA Approval – Shares Soar
California-based Sonoma Pharmaceuticals (Nasdaq:SNOA) has received approval from the US Food and Drug Administration (FDA) for their antimicrobial post-therapy gel.
Shares of the company soared this morning after the announcement and, currently, the …
Top Biopharm Stocks Today: Here’s What Investors Should Know
As usual, biopharm stocks dominate the top of the small-cap stock gainers list today.
Yahoo Finance
Vericel (NASDAQ:VCEL)
Share price: $11.15 | 24h change: 15.54% | …
Dermira Stocks Plummet Over -65% Over Drug Failure
Stocks in Biopharmaceutical company Dermira have plummeted nearly -65% over the weekend on reports that its acne drug olumacostat glasaretil has failed it’s Phase 3 trials.
In a news release, Dermira announced that …
Best Pharma Stocks Today: Cascadian Therapeutics Up Over 70%
Looking for the best pharma stocks to invest in today? One of the biggest gainers by far is Cascadian Therapeutics, which, with a current share price of $10.09 USD, has been soaring with a 24-hour …
Achaogen Stock Climbing After Positive Trial Outcome
Share prices in late-stage biopharmaceutical company Achaogen (NASDAQ:AKAO) Inc. took a sharp rise today on the heels of news that the FDA positively inspected a manufacturing plant associated with the production of its drug plazomicin. …
New Strong Buy Stocks for December 14th
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP): This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increased …
Why Sangamo Therapeutics (SGMO) Could Be Positioned for a Surge
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity …
A Look at Anavex Life Sciences Corp.’s Current Standings
Anavex Life Sciences Corp. (NASDAQ:$AVXL) is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX2-73 with donepezil, ANAVEX 19-144, ANAVEX …
Impax Laboratories Inc. Plunges 5.74% During Monday Trading
As of Monday trading on November 13th, Impax Laboratories Inc. (NASDAQ:$IPXL) plunged a cool 5.74%, or a loss of $-1.05 per share, to close at $17.25.
Impax Laboratories is a pharmaceutical company, developing …